Table 1.

Characteristics of 1-10 studies included in the meta-analysis

Author (year)	Ethnicity	Cancer type	Sample size	Age	Cutoff (hTERT)	Outcome	R	95% CI		NOS score
								Lower	Upper
Gramatzki (2021)	Caucasian	GBM (IV)	298	Adult	Mutant versus wildtype	OS	1.74	1.07	2.82	7
Razis (2020)	Caucasian	Gliomas (III-IV)	77	Adult	Mutant versus wildtype	OS	1.88	1.00	3.51	8
					Mutant/IDH wildtype versus wildtype/IDH wildtype	OS	2.26	1.09	4.66
Cheng (2020)	Asian	Gliomas (II-IV)	395	All	Mutant versus wildtype	OS	1.44	0.93	2.23	7
Kessler (2020)*	Caucasian	Primary GBM (IV)	455	NA	Mutant (C228T) versus wildtype	OS	1.23	0.77	1.97	7
					Mutant (C250T) versus wildtype	OS	2.56	1.2	5.44
		Recurrent GBM (IV)			Mutant (C228T) versus wildtype	OS	0.80	0.54	1.20
					Mutant (C250T) versus wildtype	OS	1.34	0.89	2.01
Tamrakar (2019)	Asian	Gliomas (II-IV)	97	All	Mutant versus wildtype	OS	1.20	0.50	2.80	7
Kuwahara (2019)	Asian	Astrocytoma (II-III)	36	Adult	Mutant versus wildtype	OS	12.5	2.17	100.00	7
Kim (2018)	Asian	Gliomas (II-IV)	67	Adult	Mutant versus wildtype	OS	1.055	0.495	2.422	8
						PFS	1.436	0.670	3.080
Nguyen (2017)	Caucasian	Gliomas (II-IV)	303	NA	Mutant/IDH wildtype versus wildtype/IDH wildtype	OS	1.68	1.13	2.50	6
						PFS	1.57	1.05	2.36
Lee (2017)	Asian	Anaplastic Astrocytoma (III)	67	Adult	Mutant/IDH wildtype versus wildtype/IDH wildtype	OS	1.110	0.116	10.608	8
		GBM (IV)				OS	2.111	1.016	4.389
Li (2017)*	Asian	Gliomas (II-IV)	47	All	Mutant versus wildtype	OS	2.06	0.40	10.56	6
					Mutant versus wildtype	PFS	2.21	0.92	5.32

*Data extracted form survival curve. Data of hTERT promoter mutation (n=22) and hTERT expression difference (n=7) in glioma patients. GBM=Glioblastoma; hTERT=Human telomerase reverse transcriptase; IDH=Iso-citrate dehydrogenase; PFS=Progression-free survival; OS=Overall survival; NA=Not available; CI=Confidence interval; NOS=Newcastle-Ottawa Scale